Tagworks Pharmaceuticals has received CTA approval for the Phase 0/1 CleavHER trial of TGW211, a first-in-class HER2-directed radioimmunoconjugate developed with its Click-to-Release platform. Sponsored by Radboud University Medical Center, the study will evaluate safety, pharmacokinetics, and dosimetry in HER2-positive solid tumors, with first patient enrollment expected by the end of …

Tagworks Pharmaceuticals announces progress in its Phase 1 clinical trial of TGW101, a first-in-class antibody-drug conjugate (ADC) targeting TAG-72 in patients with advanced solid tumors. Following favorable safety reviews, the study has moved to the third dose level. Preliminary safety, pharmacokinetics, and early efficacy data are expected in early to …

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.